Webinar: Working with Mature, Chamber-Specific Cardiomyocytes
In North America: Tuesday 7 June 2022 at Noon EDT / 900 PDT (register here)
In Europe: Tuesday, 7 June 2022 at Noon BST / 1300 CEST (register here)
StemBioSys’ CELLvo™ Matrix Plus induces rapid and spontaneous maturation of iPSC-derived cardiomyocytes in vitro in monolayer culture. We have previously reported that this technology enables high-throughput, predictive cardiotoxicity testing by maturing cells in 96- and 384-well plate formats. Here, we discuss the next innovation in cardiomyocyte cell culture. StemBioSys will now offer chamber-specific cardiomyocytes that can be matured on CELLvo™ Matrix Plus to achieve a new level of specificity and nuance in in vitro assays. Chamber specific cardiomyocytes faithfully recreate, in vitro, nuances of the chambers that previously could not be well studied in cell culture.
About the speaker